Neuroendocrine Tumor
41
6
10
21
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.8%
4 terminated out of 41 trials
84.0%
-2.6% vs benchmark
5%
2 trials in Phase 3/4
48%
10 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 21 completed trials
Clinical Trials (41)
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor
Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
Optimal Feeding for NET Patients
Surgical Intervention and the NETest
Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors